Immune Monitoring Following B-cell Depletion in ANCA-associated Vasculitis (NALVANCA)
NALVANCA: Immune Monitoring Following B-cell Depletion in ANCA-associated Vasculitis
ANCA-associated vasculitis is a serious autoimmune disease. The standard treatment is rituximab (RTX), which depletes B-cells to control inflammation. However, identifying patients at high risk of relapse remains a challenge, often leading to unnecessarily long treatments and side effects. Recent research suggests that RTX also impacts CD8+ T-cells, which could serve as valuable markers for better disease monitoring.
The main goal of the NALVANCA cohort is to identify biomarkers within these CD8+ T-cells. Researchers aim to find biological signals that respond to treatment and can predict a relapse. By studying these markers at the start of therapy and during the immune recovery phase, the study hopes to personalize treatment duration and management for each patient.
Recruitment targets adult patients diagnosed with ANCA-associated vasculitis. Participants must provide written informed consent for the use and storage of their blood samples in a biocollection. The protocol involves long-term monitoring with regular sampling to track changes in immune cells alongside the patient's clinical health.
研究概览
地位
地位
条件
条件
干预/治疗
干预/治疗
研究类型
研究类型
注册 (估计的)
注册
联系人和位置
学习联系方式
学习联系方式
- 姓名:Antoine Néel, Pr
- 电话号码:+33.2.40.08.33.55
- 邮箱:antoine.neel@chu-nantes.fr
学习地点
-
-
Loire-atlantique
-
Nantes、Loire-atlantique、法国、44093
- CHU de Nantes
-
接触:
- Antoine Néel, Pr
- 电话号码:+33.2.40.08.33.55
- 邮箱:antoine.neel@chu-nantes.fr
-
-
参与标准
资格标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
Inclusion criteria :
- Adult patient (age ≥ 18 years).
- Patient affiliated with the French social security system.
- Seropositive ANCA-associated vasculitis (AAV) (positive for anti-PR3 or anti-MPO) meeting the Chapel-Hill classification criteria.
- Patient scheduled to receive rituximab (RTX) maintenance therapy (500 mg every 6 months) following an initial flare or a relapse of the disease.
Exclusion Criteria:
- Patient unable to provide informed consent.
- Patient refusing to participate in the study.
- End-stage renal disease.
- Progressive neoplasia (excluding cutaneous carcinomas)
学习计划
研究是如何设计的?
设计细节
团体/队列数
队列和干预
团体/队列团体/队列 |
干预/治疗干预/治疗 |
|---|---|
|
NALVANCA Cohort - ANCA-associated vasculitis patients treated with Rituximab.
This cohort follows adult patients with ANCA-associated vasculitis, a systemic autoimmune disease.
The intervention of interest is Rituximab (RTX) therapy, used to induce B-cell depletion.
The study involves longitudinal monitoring with the systematic collection of biological samples at key time points: before treatment induction, during the depletion phase, and upon immune reconstitution (2 years after the last injection or at relapse).
The objective is to study the pleiotropic effects of B-cell depletion on CD8+ T-cells to identify biomarkers capable of predicting the risk of relapse.
|
systematic collection of additional biological samples (blood volume)
BVAS (Birmingham Vasculitis Activity Score) and VDI (Vasculitis Damage Index) are standardized clinical assessment tools used in vasculitis studies.
BVAS is a physician-reported score that evaluates current disease activity across organ systems, capturing the presence and severity of active vasculitic manifestations.
In contrast, VDI measures accumulated and irreversible organ damage resulting from vasculitis and/or its treatment over time, irrespective of current disease activity.
Together, these instruments allow comprehensive evaluation of both disease activity and long-term patient outcomes in clinical trials.
|
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Identification of a CD8+ T-cell signature sensitive to B-cell depletion.
大体时间:From diagnosis up to 2 years after the final rituximab infusion
|
Identification of a CD8+ T-cell biomarker demonstrating dual sensitivity: during rituximab-induced depletion (pre- vs. post-RTX comparison) and during immune reconstitution (comparison of samples under treatment vs. 2 years post-treatment or at relapse).
|
From diagnosis up to 2 years after the final rituximab infusion
|
次要结果测量
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
To characterize the relationship between B-cell immune responses and CD8 T-cell responses in patients with ANCA-associated vasculitis.
大体时间:From diagnosis up to 2 years post-treatment.
|
From diagnosis up to 2 years post-treatment.
|
|
To identify potential immune biomarkers associated with disease phenotype and outcomes, including CD4 T-cell subsets, regulatory T cells (Tregs), innate lymphoid cells, immunoglobulins, and inflammatory markers.
大体时间:From diagnosis up to 2 years post-treatment.
|
From diagnosis up to 2 years post-treatment.
|
|
To evaluate the association between lymphocyte-related immune biomarkers and the occurrence of intercurrent clinical events, including infectious and cardiovascular complications.
大体时间:From diagnosis up to 2 years post-treatment.
|
From diagnosis up to 2 years post-treatment.
|
合作者和调查者
调查人员
调查人员
- 首席研究员:Nicolas Degauque, PhD、CR2TI - UMR1064 (INSERM)
研究记录日期
研究主要日期
学习开始 (估计的)
学习开始
初级完成 (估计的)
初级完成
研究完成 (估计的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
其他研究编号
- RC19_0417
- 2026-A00620-51 (其他标识符:ANSM)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.